SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-010846
Filing Date
2022-02-02
Accepted
2022-02-02 16:13:30
Documents
12
Period of Report
2022-01-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm221371d12_8k.htm   iXBRL 8-K 30957
  Complete submission text file 0001104659-22-010846.txt   204412

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nbrv-20220128.xsd EX-101.SCH 3030
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nbrv-20220128_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nbrv-20220128_pre.xml EX-101.PRE 22593
6 EXTRACTED XBRL INSTANCE DOCUMENT tm221371d12_8k_htm.xml XML 3632
Mailing Address 414 COMMERCE DRIVE STE 120 FORT WASHINGTON PA 19034
Business Address 25-28 NORTH WALL QUAY DUBLIN L2 D01 H104 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 22583764
SIC: 2834 Pharmaceutical Preparations